ASH 2023 | Dual-targeting bispecific antibody alnuctamab in R/R multiple myeloma
Maria Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, discusses alnuctamab as a treatment for patients with relapsed/refractory (R/R) multiple myeloma (MM). The bispecific antibody alnuctamab elicits an immune response through dual targeting of B-cells via the B-cell maturation antigen (BCMA) and T-cells via CD38, which means its specificity is potentially higher than other BCMA inhibitors. Dr Mateos comments on the overall response rate (ORR), complete response (CR) rate, and progression-free survival (PFS) observed with subcutaneous administration of the agent (NCT03486067). The results to date show that alnuctamab is comparable, in terms of safety and efficacy, to other BCMA-targeting bispecific antibodies. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: BMS-Celgene, Janssen, Abbvie, GSK, Amgen, Takeda, Oncopeptides, Sanofi, Pfizer, Regeneron, Stemline; Membership on an entity’s Board of Directors or advisory committees: BMS-Celgene, Janssen, Abbvie, GSK, Oncopeptides, Sanofi, Pfizer, Stemline; Current Employment: University of Salamanca/Gerencia Regional de Salud de Castilla y León.
